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Abstract
Background and aims
Experimental data suggest that the HLA-DQ2 gene dose has a strong quantitative effect on
clinical outcomes and severity of celiac disease (CD). We aimed to conduct a meta-analysis
with systematic review to investigate the association between HLA-DQB1*02 gene doses
and the characteristics of CD.
Methods
We searched seven medical databases for studies discussing HLA-DQB1 gene dose in CD
and various disease characteristics, such as clinical presentation, histology, age at diagno-
sis, and comorbidities. Odds ratios (OR, for categorical variables) and weighted mean differ-
ences (for age) were calculated to compare patients with a double dose of HLA-DQB1*02
versus those with single and zero doses. Heterogeneity was tested with I2-statistics and
explored by study subgroups (children and adults).
Results
Twenty-four publications were eligible for meta-analysis. Classical CD was more frequent
with a double versus single dose of the HLA-DQB1*02 allele (OR = 1.758, 95%CI: 1.148–
2.692, I2 = 0.0%). In pediatric studies, gene dose effect was more prominent (OR = 2.082,
95%CI: 1.189–3.646, I2 = 0.0% and OR = 3.139, 95%CI: 1.142–8.630, I2 = 0.0% for the
comparisons of double versus single and double versus zero dose, respectively). Atrophic
histology was more prevalent with a double versus zero dose (OR = 2.626, CI: 1.060–6.505,
I2 = 21.3%). We observed no gene dose effect regarding diarrhea, age at diagnosis, the
severity of villous atrophy, and the association with type 1 diabetes mellitus.
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Conclusion
A double dose of HLA-DQB1*02 gene seems to predispose patients to developing classical
CD and villous atrophy. Risk stratification by HLA-DQB1*02 gene dose requires further clar-
ification due to the limited available evidence.
Introduction
Celiac disease (CD) is an immune-mediated systemic disorder triggered by gluten that occurs
in genetically susceptible individuals [1, 2]. CD is characterized histologically by small intesti-
nal mucosal damage, clinically by various intestinal and extraintestinal manifestations.
The presence of HLA-DQ2 or DQ8 is essential in the disease pathogenesis. T-lymphocytes
recognize gliadin peptides presented by antigen presenting cells expressing DQ2 or DQ8 on
cell surface, exclusively. Therefore, theoretically, either haplotype must be present in all CD-
patients [3].
HLA-DQ2 is present in up to 90–95% of celiac cases. The HLA-DQ2 heterodimer consists
of an α and a β subunit encoded by HLA-DQA1�05 and HLA-DQB1�02 alleles on chromo-
some 6, respectively [3]. Alleles are located on the same chromosome in cis configuration
(DR3/DQ2 haplotype) or separately on homologous chromosomes in trans configuration
(DR5/DQ7 and DR5/DQ2 haplotypes) [3]. The two types of DQ2 heterodimers are DQ2.5
(DQA1�0501/B1�0201) and DQ2.2 (DQA1�0201/B1�0202). Patients with heterodimers of
DQ2.5 carry a high risk and with heterodimers of DQ2.2 carry a low risk of CD [2, 4, 5].
DQ2.2 molecules are structurally similar to DQ2.5, but the latter’s gluten peptide-binding
properties are less prominent [3, 4, 6]. Those with DQ2.2 haplotype are at high risk of CD but
only if they are DQ2.2/2.5 or DQ2.2/DQ7 heterozygotes. In the latter case, functional DQ2.5
molecules can be assembled from α and β chains encoded separately on different chromo-
somes (DQA1�0505 and DQB1�0202, respectively); this constitution is called ‘DQ2 in trans’
[2, 5, 7, 8]. HLA-DQ8 is found up to 5–10% of CD patients, whose α and β chains are encoded
by HLA-DQA1�0301 and HLA-DQB1�0302, respectively (that is, DR4/DQ8 haplotype with
DR4-linked inheritance). A small minority of patients have half of the DQ2 heterodimer
(either DQA�05 or DQB�02); however, it seems to be sufficient for effective antigen presenta-
tion [2, 5, 8].
Since the DQ2 molecule plays a crucial role in CD pathogenesis, the number of HLA
DQB1�0201 copies might have important consequences in CD patients: 4 αβ-chain combina-
tions can be synthesized in heterozygotes but all HLA-DQ molecules are identical in homozy-
gotes [5, 9, 10]. Experimental data support this connection: HLA-DQ2.5 homozygotes can
present gluten peptides on antigen-presenting cells more effectively than HLA-DQ2.5 hetero-
zygotes [4, 5]. HLA-DQ2.5 homozygotes are at fivefold risk of CD as compared to HLA-
DQ2.5 heterozygotes [6, 9–11]. The presence of a second β chain seems decisive in determin-
ing the risk, whereas the role of a second α chain appears less important [10, 12, 13]. The mag-
nitude of immune response depends on gene dose: HLA-DQ2.5 homozygotes show maximal
T-cell activation and proinflammatory response, whereas heterozygotes exhibit less prominent
responses. The more DQ2.5 molecules are expressed on antigen presenting cells, the stronger
the immune activation is [4–6]. Based on these in vitro immunological studies, one might
assume that HLA-DQ2 homozygosity alters the course of CD; furthermore, the gene dose
effect is manifested clinically with an increased risk of complications [14].
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To our best knowledge, no meta-analyses have been conducted on the clinical effects of
HLA-DQB1�02 gene dose in CD. It is assumed that patients with a double dose of HLA-
DQB1�02 exhibit worse clinical outcomes, though some papers reported on how HLA-DQ2
gene dose (i.e., the number of DQB1�02 alleles) is associated with CD phenotype. This meta-
analysis aims to investigate the association between HLA-DQB1�02 gene dose and the disease
characteristics.
Materials and methods
We conducted our meta-analysis observing the rules of the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analysis (PRISMA) Statement (S1 Appendix) [15].
Search
PubMed (MEDLINE), Embase, Cochrane Controlled Register of Trials (CENTRAL), Web of
Science, WHO Global Health Library, ClinicalTrials.gov, and Scopus were searched for articles
discussing gene dose effect from inception until 22nd October 2018. Our query was “celiac
AND (homozyg� OR heterozyg� OR "gene dose" OR "gene dosage" OR "double dose" OR
"double dosage" OR "single dose" OR "single dosage" OR "zero dose" OR "zero dosage" OR
DQB1 OR DQ2.5 OR DQ2.2 OR DQ7 OR DQ8 OR "DQ2 in trans")”. Reference lists and cit-
ing articles of the relevant studies were hand-searched for further papers. No filters were
imposed upon the search. Draft of search in Embase is presented in S2 Appendix.
Our PICO format was, as follows: (P) celiac disease, (I1) zero-dose HLA-DQB1
�02, (I2) sin-
gle-dose HLA-DQB1�02, (C) double-dose HLA-DQB1�02, (O) celiac phenotype at diagnosis
including histological severity (atrophic vs. non-atrophic and Marsh 3c vs. Marsh 3a-b), clini-
cal presentation (classical vs. non-classical and diarrhea vs. non-diarrhea), age at onset and at
diagnosis, celiac-specific serology; concomitant immune-mediated disorders, dermatitis her-
petiformis, anemia, dental complications, and malignant tumors.
Eligibility, selection, and data extraction
We included original papers and conference abstracts, with the exclusion of case reports; and
excluded comments, letters, editorials, and review articles. Eligible study design included both
observational and experimental studies with adequate description of the genetic background
and disease characteristics.
Eligible studies discussed celiac patients diagnosed in accordance with the current guide-
lines with known gene dose of HLA-DQB1�02 (double, single, and zero doses) and reported at
least one of our predefined outcomes of patients by genotypes, separately. On inclusion, only
PCR-based HLA-typing (sequence-specific primer or oligonucleotide probes) was acceptable.
Outcomes included clinical presentation dichotomized into classical and non-classical phe-
notype according to the Oslo criteria. Classical and non-classical CD are defined by the pres-
ence and absence of signs and symptoms of malabsorption (i.e., diarrhea, steatorrhea, weight
loss, or growth failure), respectively [16], or into groups with and without diarrhea. Age at
diagnosis and at disease onset were assessed separately. On one hand, diagnostic histology was
divided into atrophic (Marsh 3 grade) and non-atrophic (Marsh 0–2 grades) mucosal damage
[17]. On the other hand, we analyzed the severity of villous atrophy graded by the Marsh-
Oberhuber classification (Marsh 3c vs. Marsh 3a-b) [18]. Tissue transglutaminase antibodies
and endomysial antibodies were in the focus when discussing diagnostic serology. Other out-
comes included disease complications and comorbid conditions (i.e., anemia, osteoporosis,
autoimmunity, dental complications, dermatitis herpetiformis, malignant tumors, and type 1
diabetes mellitus).
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We combined the yield of search in a reference manager software (EndNote X7.4, Clarivate
Analytics, Philadelphia, PA, US), followed by the removal of overlaps between database con-
tent and duplicate records. The duplicate-free pool was searched first by title, then by abstracts,
and full-texts against our eligibility criteria. Each phase of selection was carried out by two
independent review authors (PV and KS) in duplicate, discrepancies were resolved by third
party (MS) arbitration. Investigators had no contact with the authors of the original papers.
The following data were collected by two investigators onto pre-constructed Excel sheets:
publication data, study design, population (numbers and characteristics of participants),
HLA-DQB1�02 gene dose, age at onset; age, histology, serology, clinical presentation, anemia
at diagnosis; concomitant immune-mediated disorders and complications: type 1 diabetes
mellitus, dermatitis herpetiformis, dental enamel defect, recurrent aphthous stomatitis, enter-
opathy-associated T-cell lymphoma (EATL), small bowel carcinoma (SBC).
In the case of articles giving only HLA-DQ genotype, HLA-DQB1�02 gene dose was calcu-
lated, as follows: double-dose—HLA-DQ2.5 homozygotes (DQ2.5/DQ2.5) and compound
heterozygotes (DQ2.5/DQ2.2); single-dose—HLA-DQ2.5 heterozygotes (DQ2.5/DQX) and
HLA-DQ2 in trans (DQ2.2/DQ7); and zero-dose—HLA-DQ8/DQX and HLA-DQ2.2/DQX,
where X represents any alleles except for DQ2.5 [8, 19–28].
Risk of bias assessment
Two authors (MB and EP), unblinded to publication data, assessed the methodological quality
of each study by using a tool developed a priori by our review team based on the Newcastle-
Ottawa Scale (S1 Table). Results of risk of bias assessment were taken into account when
assessing the limitations of the individual studies.
Statistical analysis
A biostatistician (NF) carried out the statistical analysis by using Comprehensive Meta-Analy-
sis software (Version 3, Biostat, Englewood, NJ). The random effect model with DerSimonian-
Laird estimation was used for analysis [29]. For dichotomous outcomes (i.e., histology, clinical
presentation, and diarrhea), we calculated odds ratios (ORs) and 95% confidence interval
(CIs). For age at diagnosis, weighted mean difference (MD) and 95% CIs were calculated. Sta-
tistical significance was attained when p<0.05.
Heterogeneity was tested with I2- and chi2-tests. An I2 of 0%-40%, 30%-60%, 50%-90%, and
75%-100% represented not important, moderate, substantial, and considerable between-study
heterogeneity with p<0.10 indicating statistical significance [30]. Since the clinical phenotype
of CD diagnosed in childhood and adulthood may differ, we planned to set up study subgroups
by age (children and adults) in each plot [31–35]. The number of studies was insufficient for
meta-regression by gene dose.
Funnel plots were used to assess publication bias.
Sensitivity analysis was performed by omitting studies one-by-one from the analyses and
recalculating the pooled effect.
Results
Search and selection
Fig 1. shows the flowchart of this work. Our search strategy yielded 6704 records (PubMed
[MEDLINE]: 954, Embase: 2277, CENTRAL: 43, Web of Science: 925, WHO Global Health
Library: 795, ClinicalTrials.gov: 6, and Scopus: 1704). Out of a total of 59 papers eligible for
qualitative synthesis (Table 1 and S2 Table) [7, 8, 12–14, 19–28, 36–79], 24 were included in
HLA-DQB1*02 gene dose effect in celiac disease
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meta-analysis (Table 1) [8, 12, 19–28, 36–47]. Results of meta-analysis are summarized in
Table 2, raw data on disease characteristics are presented in S3 Table.
Clinical presentation
Five studies [22, 23, 38, 43, 47] were included in the comparison of classical vs. non-classical
CD regarding double vs. single dose of HLA-DQB1�02; of them, four [22, 23, 38, 43] were
included in the analysis regarding double vs. zero dose of HLA-DQB1�02. Patients with a dou-
ble dose of HLA-DQB1�02 had classical CD more frequently, compared to those having a sin-
gle dose of the allele (OR = 1.758, CI: 1.148 to 2.692, p = 0.009) in a homogeneous dataset (I2 =
0.0%, p = 0.744) (Fig 2). The difference was more prominent in the subgroup of children
(OR = 2.082, CI: 1.189 to 3.646, p = 0.010) in a homogeneous dataset (I2 = 0.0%, p = 0.609)
(Fig 2). In the analysis of a double dose of HLA-DQB1�02 vs. a zero dose of the allele, we
detected a significant gene dose effect only if children were included in the analysis
(OR = 3.139, CI: 1.142 to 8.630, p = 0.027) in a homogeneous dataset (I2 = 0.0%, p = 0.747)
(Fig 3). Setting up the subgroup of children reduced the heterogeneity from 40.7% to 0.0% (Fig
3).
Five studies [24, 26, 28, 40, 44] reported on the presence of diarrhea at diagnosis, all were
included in the analysis of double vs. single dose of HLA-DQB1�02 and that of double vs. zero
dose of the allele, as well. We failed to detect a significant gene dose effect, nor in the subgroups
of children and adults in a homogeneous dataset (I2 = 0.0%) (Table 2, S1 and S2 Figs).
Age at diagnosis
Four [28, 36, 41, 43] and five studies [28, 36, 41, 43, 47] were included in the comparison of
double vs. zero dose of HLA-DQB1�02 and double vs. single dose of the allele concerning age
at diagnosis, respectively. Patients with a double dose of HLA-DQB1�02 were similar in age at
Fig 1. Flow chart of meta-analysis.
https://doi.org/10.1371/journal.pone.0212329.g001
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Table 1. Characteristics of included studies.
Author (year) Country Settings N0 of pts. Age group Genotyping
Method Target of typing within
the study
N0 of pts.
(double/single/
zero dose)
Akar et al. (2015)
[36]
Turkey prospective, single
center, cross-sectional
36 CD pts children PCR-SSP HLA-DQB1�0201 allele
dose
5/24/7
Araya et al. (2015)
[19]
Chile prospective, single
center, case-control
56 CD pts and 166
first degree relatives
children and
adults
PCR-SSP HLA-DQ genotype 12/25/7
Bastos et al. (2017)
[20]
Brazil prospective,
multicenter, case-
control
66 CD pts and 32
CD/T1DM pts
not reported
(median age 14
years)
RT-PCR HLA-DQ genotype 16/52/30
Cabrera et al. (2018)
[21]
Spain prospective, single
center, case-control
196 CD pts and 206
healthy control
children PCR-SSO HLA-DQ genotype 79/103/14
Cakir et al. (2014)
[22]
Turkey prospective, single
center, cross-sectional?
78 CD pts children PCR-SSO HLA-DQ genotype 28/34/14
Colombe et al.
(2015) [37]
USA retrospective, single
center, cross-sectional
89 CD pts adults PCR-SSP HLA-DQB1�0201 allele
dose
45/7/37
Congia et al. (1994)
[38]
Italy prospective, single
center, case-control
62 CD pts and 89
healthy control
children and
adults
PCR-SSO HLA-DQB1�0201 allele
dose
30/31/1
Eller et al. (2006)
[39]
Israel prospective, single
center, cross-sectional
175 Beduin kindred children and
adults
PCR-SSO HLA-DQB1�0201 allele
dose
3/3/0
Greco et al. (1998)
[40]
Italy prospective, single
center, cross-sectional
145 CD pts children PCR-SSO HLA-DQB1�02 allele
dose
46/84/15
Gudjonsdottir et al.
(2009) [23]
Sweden,
Norway
prospective, multi-
center, cross-sectional
224 CD pts (HLA
status was available:
98 pts)
children and
adults
PCR-SSO HLA-DQ genotype 40/52/6
Hanif et al. (2017)
[24]
Pakistan prospective, single
center, observational
12 CD pts children PCR HLA-DQ genotype 5/7/0
Jores et al. (2007)
[12]
Italy retrospective, single
center, cross-sectional
187 CD pts children PCR-SSO HLA-DQB1�0201 allele
dose
77/93/17
Kabatova et al.
(2017) [25]
Slovakia retrospective, single
center, cross-sectional
258 CD pts (HLA
status was available:
217 pts)
children PCR-SSP HLA-DQ genotype 42/97/78
Karinen et al. (2006)
[41]
Finland prospective, single
center, cross-sectional
144 CD pts (only
siblings from 52
families)
adults PCR-SSP HLA-DQB1�0201 allele
dose
32/103/9
Mohammed et al.
(2014) [42]
Egypt prospective, single
center, case-control
31 CD/T1DM pts children and
adults
PCR-SSP HLA-DQB1�02 allele
dose
16/8/7
Nenna et al. (2008)
[43]
Italy prospective, single
center, cross-sectional
124 CD pts children PCR-SSP HLA-DQB1�02 allele
dose
26/85/13
Ros et al. (2010)
[26]
Spain retrospective, single
center, cross-sectional
396 CD pts children PCR-SSO HLA-DQ genotype 168/206/17
Rostami-Nejad et al.
(2014) [8]
Iran retrospective,
multicenter, case-
control
59 CD pts and 151
healthy control
children and
adults
PCR-SSP HLA-DQ genotype 15/30/14
Schweiger et al.
(2016) [27]
Slovenia prospective, single
center, case-control
68 CD pts vs 69 CD/
T1DM pts
children PCR-SSO
and -SSP
HLA-DQ genotype 41/81/12
Thomas et al. (2009)
[44]
UK retrospective, single
center, cross-sectional
384 CD pts (HLA
status was available:
360 pts)
adults PCR-SSP HLA-DQB1�0201 allele
dose
71/247/42
Vegas-Sanchez et al.
(2015) [45]
Spain retrospective, single
center, cross-sectional
14 CD pts adults PCR-SSO HLA-DQB1�0201 allele
dose
2/7/3
Vermeulen et al.
(2009) [28]
The
Netherlands
retrospective, single
center, cross-sectional
113 CD pts children PCR-SSO HLA-DQ genotype 45/58/10
(Continued)
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diagnosis, compared to their counterparts with single and zero doses of the allele (MD: -0.523,
CI: -1.630 to 0.585, p = 0.355; I2 = 28.60% and MD: -7.332, CI: -19.833 to 5.169, p = 0.250; I2 =
Table 1. (Continued)
Author (year) Country Settings N0 of pts. Age group Genotyping
Method Target of typing within
the study
N0 of pts.
(double/single/
zero dose)
Viken et al. (2017)
[46]
Norway retrospective,
multicenter, case-
control
327 CD pts and 215
CD/T1DM pts
children PCR-SSP HLA-DQB1�0201 allele
dose
141/321/78
Zubillaga et al.
(2002) [47]
Spain prospective, single
center, cross-sectional
133 CD pts children PCR-SSP HLA-DQB1�02 allele
dose
63/63/7
CD: celiac disease; PCR-SSP: polymerase chain reaction with sequence-specific primers; PCR-SSO: polymerase chain reaction with sequence-specific oligonucleotide
probes, Pts: patients RT-PCR: real-time polymerase chain reaction; T1DM: type 1 diabetes mellitus.
https://doi.org/10.1371/journal.pone.0212329.t001
Table 2. Results of meta-analysis.
Outcomes,
subgroups by age
Double vs. single dose of HLA-DQB1�02 Double vs. zero dose of HLA-DQB1�02
N0 of patients OR (95% CI), p-value Heterogeneity
(I2, chi2)
N0 of patients OR (95% CI), p-value Heterogeneity
(I2, chi2)
Atrophic vs. non-
atrophic
722 0.991 (0.406–2.420), p = 0.984 11.8%, p = 0.338 430 2.626 (1.060–6.505), p = 0.037� 21.3%, p = 0.260
children 237 1.729 (0.319–9.370), p = 0.525 71.6%,
p = 0.061�
159 1.757 (0.236–13096), p = 0.583 0.0%, p = 0.542
adults 379 0.537 (0.175–1.652), p = 0.278 0.0%, p = 0.682 200 2.534 (0.675–9.507), p = 0.168 0.0%, p = 0.945
Marsh 3c vs. Marsh 3a-b 862 0.870 (0.514–1.470), p = 0.602 39.7%, p = 0.127 418 0.822 (0.333–2.032), p = 0.671 46.8%,
p = 0.068�
children 399 0.821 (0.401–1.681), p = 0.590 0.0%, p = 0.397 251 0.975 (0.296–3.208), p = 0.967 65.2%,
p = 0.035�
adults 442 0.957 (0.420–2.184), p = 0.918 82.4%,
p = 0.017�
147 0.753 (0.157–3.599), p = 0.722 50.2%, p = 0.134
Classical vs. non-
classical
458 1.758 (1.148–2.692), p = 0.009� 0.0%, p = 0.744 221 1.701 (0.725–3.991), p = 0.222 40.7%, p = 0.168
children 305 2.082 (1.189–3.646), p = 0.010� 0.0%, p = 0.609 81 3.139 (1.142–8.630), p = 0.027� 0.0%, p = 0.747
Diarrhea vs. non-
diarrhea
934 1.147 (0.863–1.523), p = 0.345 0.0%, p = 0.860 421 1.092 (0.655–1.818), p = 0.337 0.0%, p = 0.856
children 616 1.143 (0.819–1.593), p = 0.432 0.0%, p = 0.727 308 1.111 (0.569–2.170), p = 0.758 0.0%, p = 0.724
adults 318 1.158 (0.671–1.998), p = 0.599 0.0%, p = 1.000 113 1.065 (0.484–2.342), p = .0875 0.0%, p = 1.000
Type 1 diabetes mellitus 840 0.914 (0.437–1.912), p = 0.811 71.8%,
p = 0.006�
411 1.169 (0.410–3.331), p = 0.770 89.8%, p<0.001�
children 766 0.597 (0.218–1.634), p = 0.315 79.3%,
p = 0.008�
365 0.242 (0.045–1.312), p = 0.100 79.4%,
p = 0.008�
MD (95% CI), p-value Heterogeneity
(I2, chi2)
MD (95% CI), p-value Heterogeneity
(I2, chi2)
Age at diagnosis 512 -0.523 (-1.630 to 0.585),
p = 0.355
28.6%, p = 0.231 147 -7.332 (-19.833 to 5.169), p = 0.250 71.4%,
p = 0.015�
children 377 -0.303 (-1.156 to 0.551),
p = 0.487
5.5%, p = 0.366 106 -2.026 (-5.824 to 1.771), p = 0.296 48.7%, p = 0.142
adults 133 -5.000 (-10.876 to 0.876),
p = 0.095
0.0%, p = 1.000 41 -15.000 (-25.509 to -4.491),
p = 0.005�
0.0%, p = 1.000
Asterisks indicate a p<0.05 for OR and MD, and a p<0.10 for heterogeneity tested with chi2-test. CI: confidence interval; OR: odds ratio; MD: mean difference.
https://doi.org/10.1371/journal.pone.0212329.t002
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71.4% respectively) (S3 and S4 Figs). In the subgroup of children, heterogeneity was consider-
ably reduced (Table 2).
Histology at diagnosis
Eight studies [8, 19, 25, 37, 42–45] were eligible for inclusion in the comparison of atrophic vs.
non-atrophic histology, all were included in the analysis of double vs. single dose of
Fig 2. Odds ratios of classical presentation of CD at diagnosis with double dose vs. single dose of HLA-DQB1�02.
Patients with a double dose of HLA-DQB1�02 had classical CD more frequently compared to those having a single
dose. This association was more prominent in children. Heterogeneity of the groups overall: I2 = 0.0%, p = 0.744;
heterogeneity of the subgroup of children: I2 = 0.0%, p = 0.609. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0212329.g002
Fig 3. Odds ratios of classical presentation of CD at diagnosis with double dose vs. zero dose of HLA-DQB1�02. A
significant gene dose effect was detected in the subgroup of children. Heterogeneity of the groups overall: I2 = 40.7%,
p = 0.168; heterogeneity of the subgroup of children: I2 = 0.0%, p = 0.747. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0212329.g003
HLA-DQB1*02 gene dose effect in celiac disease
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HLA-DQB1�02 and that of double vs. zero dose of the allele, as well. Villous atrophy at diagno-
sis was not more frequent in patients with a double dose of HLA-DQB1�02, as compared to a
single dose of the allele (OR = 0.991, CI: 0.406 to 2.420, p = 0.984) in a homogeneous dataset
(I2 = 11.8%, p = 0.338) (Fig 4). In contrast, patients with a double dose of the allele were more
likely to have villous atrophy at diagnosis than those with a zero dose of the allele (OR = 2.626,
CI: 1.060 to 6.505, p = 0.037) (Fig 5). The subgroup analysis of children and adults did not
result in significances across groups (Figs 4 and 5, Table 2).
Regarding the severity of villous atrophy, seven [12, 24, 25, 41–44] and eight studies [12,
24, 25, 41–45] were eligible for inclusion in the analysis of double vs. single dose of HLA-
DQB1�02 and that of double vs. zero dose of the allele. Marsh 3c at diagnosis was not more fre-
quent in patients with a double dose of HLA-DQB1�02, as compared to single and zero doses
of the allele (OR = 0.870, CI: 0.514 to 1.470, p = 0.602 [I2 = 39.7%, p = 0.127] and OR = 0.822,
CI: 0.333 to 2.032, p = 0.671 [I2 = 46.8%, p = 0.068], respectively). These remained unchanged
in the subgroups of children and adults (S5 and S6 Figs, Table 2).
Type 1 diabetes mellitus
Five [20, 21, 27, 39, 46] studies were included in the analysis of double vs. single dose of
HLA-DQB1�02; of them, four [20, 21, 27, 46] were eligible for inclusion in the analysis of dou-
ble vs. zero dose of the allele. Analyses revealed no significant gene dose effect concerning the
coexistence of type 1 diabetes mellitus and CD, which remained unchanged in the subgroups
of children and adults. All analyses suffered from significant heterogeneity (S7 and S8 Figs,
Table 2).
Other patient and disease characteristics
There were several reports on the association between HLA-DQ2 gene dose effect and the clin-
ical phenotype of CD (age at onset, anemia, serology, autoimmunity, body mass index, osteo-
porosis, oral manifestations, complicated CD, and dermatitis herpetiformis). Data reported
were insufficient for quantitative synthesis. We report the studies and the direction of associa-
tions with HLA-DQ gene dose in Table 3.
Publication bias
Although funnel plots seem symmetric, the low number of studies raised concerns about an
uncertain assessment of symmetry (S3 Appendix).
Sensitivity analysis
When we omitted studies one-by-one, there was no change in the direction of the main associ-
ation, except for two outcomes. Omitting Zubillaga et al. from the analysis on classic vs. non-
classic clinical presentation resulted in the loss of statistical significance in the comparison of
double vs. single dose. Omitting Vermeulen et al. from the analysis on age at diagnosis,
resulted in a significant gene dose effect (MD = -0.248, CI: -0.464 to -0.032, p = 0.024) in the
comparison of double vs. single dose.
Risk of bias assessment
Results of risk of bias assessment are presented in Fig 6. Ten out of 24 studies (41.7%) aimed to
analyze gene dose effect primarily. Twenty-two out of 24 (91.7%) and 18 out of 24 (75.0%)
studies used a low-risk classification for diagnosing CD and rating diagnostic histology,
HLA-DQB1*02 gene dose effect in celiac disease
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respectively. However, the average CD population was clearly represented only in 62.5% of the
studies included. Appropriate blinding was applied in only one study (4.2%).
Discussion
We aimed to review the current knowledge about the influence of HLA-DQB1�02 gene dose
on the phenotype of celiac disease in our study.
Although reasonable molecular mechanisms have been proposed by in vitro experiments
[5, 6], gene dose effect seemed to influence only the clinical phenotype defined by Oslo criteria
and histology. Patients with a double dose of HLA-DQB1�02 exhibited more often classical
phenotype and villous atrophy, as compared to those with a single dose of the allele, whereas
no evidence of gene dose effect was collected on diarrhea, age at diagnosis, the severity of vil-
lous atrophy, and the frequency of type 1 diabetes mellitus (Table 2).
Lack of clinically significant gene dose effect is also supported by experimental results, as
well: (1) an equal magnitude of specific T-cell responses characterizes homo- and heterozy-
gotes, (2) the amount of DQA1�05 and DQB1�02 mRNS in heterozygotes exceeded the
expected 50% of that measured in homozygotes [80]. Other factors should be taken into con-
sideration, e.g., complementing HLA risk stratification with ten non-HLA loci changed the
allocation of 10% of study population from the moderate- to the high-risk group [81]. The
effect of non-HLA loci may outweigh that of HLA. In addition, non-genetic (environmental)
factors appear to contribute to CD phenotype [23, 28, 40].
Concerning comorbid conditions, data allowed us to perform analysis only on type 1 diabe-
tes mellitus, which is the most frequent co-existing immune-mediated disorder in CD. We
Fig 4. Odds ratios of atrophic histology at diagnosis with double dose vs. single dose of HLA-DQB1�02. We failed to detect a
significant gene dose effect regarding diagnostic histology. Heterogeneity of the groups overall: I2 = 11.8%, p = 0.338; heterogeneity of
the subgroup of adults: I2 = 0.0%, p = 0.682; heterogeneity of the subgroup of children: I2 = 71.6%, p = 0.061. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0212329.g004
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failed to observe a significant gene dose effect in the frequency of type 1 diabetes mellitus. This
corroborates with previous studies confirming that the combined occurence of DQ2 and DQ8
is high in patients with both CD and type 1 diabetes mellitus [27, 46, 54].
Fig 5. Odds ratios of atrophic histology at diagnosis with double dose vs. zero dose of HLA-DQB1�02. Patients with a
double dose of the allele were more likely to have villous atrophy at diagnosis than those with a single dose of the allele.
Heterogeneity of the groups overall: I2 = 21.3%, p = 0.260; heterogeneity of the subgroup of adults: I2 = 0.0%, p = 0.945;
heterogeneity of the subgroup of children: I2 = 0.0%, p = 0.542. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0212329.g005
Table 3. Summary of studies reporting on gene dose effect.
Characteristics Association between HLA-DQ2 gene dose and the clinical phenotype
Positive No association Negative
Clinical presentation [38, 41, 43, 47, 51, 66, 69, 79] [7, 12, 23, 26, 28, 36, 40, 44, 61, 71, 72, 74]
Age at onset [47] [26, 40, 45, 53, 71, 73, 75–77]
Age at diagnosis [38, 41, 47, 66] [28, 36, 40, 44, 71, 72] [13, 68]
Histology at diagnosis [12, 37, 41, 43, 78] [7, 28, 36, 44, 53, 69, 71]
Anemia [41] [26, 36, 40, 43, 44]
Serology [7, 42, 43, 67, 69, 70] [36, 44, 48, 59, 65, 71, 78]
Autoimmunity [27, 39, 62] [64] [46, 54]
Body mass index [26, 44]
Osteoporosis [44]
Oral manifestations (DED, RAS) [55, 63] [44]
Complicated disease (RCD, EATL, SBC) [14, 49, 50, 64] [58]
Dermatitis herpetiformis [57]
DED: dental enamel defect; EATL: enteropathy-associated T-cell lymphoma; RAS: recurrent aphthous stomatitis; RCD: refractory celiac disease; SBC: small bowel
carcinoma.
https://doi.org/10.1371/journal.pone.0212329.t003
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Although we were unable to meta-analyze other disease complications due to discrepancies
in reporting, the importance of HLA-DQ2 gene dose might be highlighted by these studies
(Table 3). HLA status appears to be important in the development of malignant complications.
Lymphomatous complications were more frequent in patients with a double dose of
HLA-DQ2 in a study [64]. In a prospective study conducted by Al-Toma et al., HLA-DQ2.5
homozygosity was associated with serious CD complications, namely, type 2 refractory celiac
disease and enteropathy-associated T-cell lymphoma [14]. Prevalence of DQ2 homozygosity
was significantly higher in patients with a complicated disease (i.e., patients with type 1 and
type 2 refractory CD, EATL, or SBC), as compared to those with non-complicated CD in a ret-
rospective Italian and a multicentre study [49, 50]. However, it is noteworthy that data of
Howell et al. did not confirm these observations [58]. Further studies aiming to resolve these
controversies are awaited to test whether determining HLA gene dose is appropriate for risk
stratification for severe complications.
Strengths and limitations
To date, no meta-analyses have investigated HLA-DQB1�02 gene dose effect in CD. Our main
strength is the transparent and comprehensive search and the rigorous selection process; how-
ever, we must acknowledge that the evidence is limited due to a number of reasons.
We did not contact the original authors of the included or excluded papers to acquire fur-
ther information; only published material was used to preserve reproducibility.
Data on the clinical phenotype of celiac disease were collected from patients’ files retrospec-
tively. Regarding HLA status, HLA-typing was performed (1) at the time of enrolment to the
study (at or after the diagnosis of celiac disease) or (2) before enrolment (retrospectively col-
lected from charts). In relation to the outcomes, both ways are retrospective. However, HLA is
a genetic marker, an unchangeable feature of the patients. Therefore, in our opinion, timing of
HLA-typing does not affect data quality.
Fig 6. Summary of risk of bias in individual studies included in meta-analysis. Green, red, and blue icons represent
low, high, and uncertain risk of bias. Definitions of items are provided in S1 Table.
https://doi.org/10.1371/journal.pone.0212329.g006
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Design of the studies included were (1) controlled studies including celiac and non-celiac
subjects (case-control or cross-sectional studies) or (2) uncontrolled case series reports of
celiac patients. In this meta-analysis, data on celiac patients were desirable, exclusively (while
the non-celiac groups were irrelevant for us). As a consequence, there were studies included
not aiming to analyze gene dose effect, as a primary objective, which may limit the data
reported from the studies.
The number of eligible studies was low, not allowing us to draw reliable conclusions from
the symmetry of the funnel plots to assess small-study effect (S3 Appendix).
Relevant clinical questions as to whether gene dose effects anemia, complications of CD, or
serology have not been meta-analyzed due to incoherent data reporting across studies (S2
Table).
As only nine studies typed HLA-DQB1�0201 [12, 36–39, 41, 44–46] (the rest of them typed
DQB1�02 allele [40, 42, 43, 47]), our conclusion is not generalizable to the role of HLA-
DQB1�0201 which may be of greater clinical importance. DQB1�02 allele dose was calculated
from DQ2 haplotype-based HLA risk stratification systems in eleven studies [8, 19–28].
Self-reported clinical symptoms (e.g., bloating, diarrhea, and abdominal discomfort) are
difficult to quantify objectively. To minimize the distortion, we used the widely accepted Oslo
classification (i.e., dichotomization of patients into classical [with malabsorption] and non-
classical [without malabsorption] phenotypes) [16].
Some analyses suffer from statistical heterogeneity (Table 2) which can be explained by
methodological heterogeneity (i.e., histological assessment, HLA-typing, inclusion and exclu-
sion of subjects) and clinical heterogeneity (i.e., geography, diverse environmental factors
[e.g., timing of gluten introduction], and genetics [i.e., HLA and non-HLA loci]). A part of
heterogeneity may originate from the age of participants: heterogeneity reduced when analyz-
ing data from children and adults separately in some analysis, while persisted in others
(Table 2).
Conclusion
Implications for clinical practice
Our results suggest a significant gene dose effect regarding clinical presentation: classical clini-
cal presentation and villous atrophy are more frequent in patients with a double dose of
HLA-DQB1. We were unable to prove a similar effect in terms of diarrhea at diagnosis, age at
diagnosis, the degree of atrophy, and type 1 diabetes mellitus. Recent guidelines do not require
HLA-typing to set up the diagnosis of CD apart from pediatric cases diagnosed without intesti-
nal biopsy. The role of it is mainly restricted to the exclusion of CD [82, 83]. Patients with
high-risk HLA status may be at higher risk of severe disease course, raising concerns about the
need for a stricter gluten-free diet and follow-up. However, these results should be treated with
caution due to the limitations of the data available for our study.
Implications for research
Studies validating our results and investigating the association between gene dose effect and
disease complications (e.g., malignant tumors [EATL, SBC], autoimmune disorders, and
RCD) are awaited.
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